Which evaluated veliparib as a potential treatment for advanced or metastatic NSCLC viagra for men.

Abbvie announces multiple research outcomes of veliparib investigational substance in NSCLC patients AbbVie released interim results from a continuing Phase 2 study of its investigational compound veliparib in conjunction with chemotherapy, which showed a 35 % improvement in progression-free of charge survival and a 30 % improvement in overall survival in sufferers with previously untreated metastatic or advanced non-little cell lung tumor . These results, which evaluated veliparib as a potential treatment for advanced or metastatic NSCLC, were provided for the very first time at the 2014 Annual Congress of the European Culture for Medical Oncology , September 26-30 in Madrid, Spain. ‘There is an urgent have to develop novel treatment plans for patients with squamous cell carcinoma,’ stated Suresh S viagra for men .